Literature DB >> 760739

The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease.

G Bodemar, B Norlander, L Fransson, A Walan.   

Abstract

1 The absorption of a single oral dose of cimetidine taken on a fasting stomach or together with a meal was studied in 28 patients before and during 12 weeks treatment with cimetidine. 2 No significant changes in bioavailability were seen during treatment measured as the area under the blood concentration curve (AUC). 3 AUC after a single dose of 400 mg cimetidine was 2.05 times the area after a 200 mg dose. 4 There was a good correlation between AUC and the dose of cimetidine given corrected for body weight (r=0.89). 5 There was no difference in bioavailability if 200 mg cimetidine was taken on a fasting stomach or together with a beef steak meal. 6. During fasting conditions there was a peak in blood concentration at about one hour followed by a second unexplained peak during the third to fifth hour after dose administration. 7 With food the initial rise in blood concentrations was slower and there was only one peak occurring about 2 h after dose administration.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 760739      PMCID: PMC1429608          DOI: 10.1111/j.1365-2125.1979.tb00892.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  High-pressure liquid chromatographic analysis of cimetidine, a histamine H2-receptor antagonist, in blood and urine.

Authors:  W C Randolph; V L Osborne; S S Walkenstein; A P Intoccia
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

2.  Influence of a meal on the absorption of cimetidine. A new histamine H2-receptor antagonist.

Authors:  R W Spence; D R Creak; L R Celestin
Journal:  Digestion       Date:  1976       Impact factor: 3.216

3.  Inhibition of food-stimulated gastric acid secretion by cimetidine.

Authors:  R E Pounder; J G Williams; R C Russell; G J Milton-Thompson; J J Misiewicz
Journal:  Gut       Date:  1976-03       Impact factor: 23.059

4.  Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.

Authors:  W L Burland; W A Duncan; T Hesselbo; J G Mills; P C Sharpe; S J Haggie; J H Wyllie
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

5.  Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer.

Authors:  R M Henn; J I Isenberg; V Maxwell; R A Sturdevant
Journal:  N Engl J Med       Date:  1975-08-21       Impact factor: 91.245

  5 in total
  30 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

Review 2.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Pharmacokinetics of cimetidine after subchronic administration.

Authors:  T W Chin; M Spino; S M MacLeod; W A Mahon; S J Soldin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Intestinal uptake of cimetidine and ranitidine in rats.

Authors:  V Mummaneni; J B Dressman
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

6.  Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs.

Authors:  V Mummaneni; G L Amidon; J B Dressman
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

7.  Cimetidine-a clinical and pharmacokinetic study.

Authors:  J Webster; H E Barber; G M Hawksworth; T A Jeffers; J Petersen; J C Petrie; P W Brunt; N A Mowat; R Griffiths
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

8.  The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults.

Authors:  J A Ziemniak; B M Assael; R Padoan; J J Schentag
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

10.  Prolactin responses to cimetidine.

Authors:  W L Burland; R I Gleadle; R M Lee; D Rowley-Jones; G V Groom
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.